Tumor-derived autophagosome vaccine: Mechanism of cross-presentation and therapeutic efficacy

Clinical Cancer Research

Volumn 17, Issue 22, 2011, Pages 7047-7057

  Li, Yuhuan ^a   Wang, Li Xin ^a,d,e   Pang, Puiyi ^a   Cui, Zhihua ^a   Aung, Sandra ^c   Haley, Daniel ^a   Fox, Bernard A ^a,b   Urba, Walter J ^b   Hu, Hong Ming ^a,b,d  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c UbiVac LLC   (United States)

^d SOUTHEAST UNIVERSITY   (China)

^e MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CLEC9A PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 94; HIGH MOBILITY GROUP B1 PROTEIN; LECTIN RECEPTOR; TUMOR DERIVED AUTOPHAGOSOME VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOPHAGY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL STRAIN HEK293; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DRUG EFFICACY; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; INTERNALIZATION; LEWIS CARCINOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE ACTIVATION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; AUTOPHAGY; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CROSS-PRIMING; CYTOKINE-INDUCED KILLER CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 81255138298     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0951     Document Type: Article

References (49)

1. Dikic I, Johansen T, Kirkin V. Selective autophagy in cancer development and therapy. Cancer Res 2010;70:3431-4.
2. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007;7:961-7. (Pubitemid 350165856)
3. Schmid D, Munz C. Innate and adaptive immunity through autophagy. Immunity 2007;27:11-21. (Pubitemid 47089030)
4. Nedjic J, Aichinger M, Mizushima N, Klein L. Macroautophagy, endogenous MHC II loading and T cell selection: the benefits of breaking the rules. Curr Opin Immunol 2009;21:92-7.
5. Heath RJ, Xavier RJ. Autophagy, immunity and human disease. Curr Opin Gastroenterol 2009;25:512-20.
6. English L, Chemali M, Duron J, Rondeau C, Laplante A, Gingras D, et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol 2009;10:480-7.
7. Schmid D, Pypaert M, Munz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 2007;26:79-92. (Pubitemid 46109341)
8. Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 2008; 68:6889-95.
9. Gueguen M, Long EO. Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen. Proc Natl Acad Sci U S A 1996;93:14692-7. (Pubitemid 26419030)
10. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol 1996;157:1823-6. (Pubitemid 126449651)
11. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F, et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003;18:343-54. (Pubitemid 36351514)
12. Li Y, Wang LX, Pang P, Twitty C, Fox BA, Aung S, et al. Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy 2009;5:576-7.
13. Heath WR, Carbone FR Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64. (Pubitemid 32368029)
14. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 2008;9:558-66. (Pubitemid 351560525)
15. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007;316:612-6. (Pubitemid 46683149)
16. Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol 2008;20:89-95.
17. Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P, et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009;458:899-903.
18. Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005;12:468-74. (Pubitemid 41150132)
19. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007;8:603-12. (Pubitemid 47106613)
20. Norbury CC, Basta S, Donohue KB, Tscharke DC, Princiotta MF, Berglund P, et al. CD8+T cell cross-priming via transfer of proteasome substrates. Science 2004;304:1318-21. (Pubitemid 38697427)
21. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000;1:151-5.
22. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007;109:4839-45. (Pubitemid 46827780)
23. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009;14:364-75.
24. Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin Teh J, Lo JC, et al. The dendritic cell subtype-restricted C-type lectinClec9A is a target for vaccine enhancement. Blood 2008;112:3264-73.
25. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 2006;176:6770-6. (Pubitemid 43787859)
26. Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for selfeating. Cell Death Differ 2005;12 Suppl 2:1542-52.
27. Kurotaki T, Tamura Y, Ueda G, Oura J, Kutomi G, Hirohashi Y, et al. Efficient cross-presentation by heat shock protein 90-peptide complex- loaded dendritic cells via an endosomal pathway. J Immunol 2007;179:1803-13.
28. Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C, et al. Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J Immunol 2006;177:3525-33. (Pubitemid 44359883)
29. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003;425:402-6. (Pubitemid 37187269)
30. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003;425:397-402. (Pubitemid 37187268)
31. Ackerman AL, Giodini A, Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during cross-presentation by dendritic cells. Immunity 2006;25:607-17. (Pubitemid 44529035)
32. Giodini A, Rahner C, Cresswell P. Receptor-mediated phagocytosis elicits cross-presentation in nonprofessional antigen-presenting cells. Proc Natl Acad Sci U S A 2009;106:3324-9.
33. Berg TO, Fengsrud M, Stromhaug PE, Berg T, Seglen PO. Isolation and characterization of rat liver amphisomes. Evidence for fusion of autophagosomes with both early and late endosomes. J Biol Chem 1998;273:21883-92. (Pubitemid 28405366)
34. Groettrup M, van den Broek M, Schwarz K, Macagno A, Khan S, de Giuli R, et al. Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol 2001;21:339-58. (Pubitemid 34208441)
35. Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD Jr. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res 2005;65:10059-67. (Pubitemid 41541488)
36. Zheng R, Cohen PA, Paustian CA, Johnson TD, Lee WT, Shu S, et al. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 2008;68:4045-9.
37. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6:769-76. (Pubitemid 43090462)
38. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer 2007;110:1677-86. (Pubitemid 47557292)
39. Murray JL, GilloglyME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002;8:3407-18. (Pubitemid 35340715)
40. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10:4699-708. (Pubitemid 38955520)
41. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 2007;7:1225-41. (Pubitemid 47521019)
42. Yewdell JW, Nicchitta CV. The DRiP hypothesis decennial: support, controversy, refinementandextension.Trends Immunol2006;27:368-73.
43. Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008;20:286-95.
44. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines 2008;7:1185-99.
45. Apetoh L,Ghiringhelli F, Tesniere A, Criollo A, OrtizC, LidereauR, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anti-cancer chemotherapy and radiotherapy. Immunol Rev 2007;220:47-59. (Pubitemid 350045573)
46. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008;20:504-11.
47. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009;9:465-79.
48. Huysamen C, Willment JA, Dennehy KM, Brown GD. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes. J Biol Chem 2008;283:16693-701.
49. Twitty CG, Jensen SM, Hu HM, Fox BA. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res 2011;17:6467-81.